Processa stockholder letter outlines Vidya deal, 309.3 million as-converted shares
Processa sent a stockholder letter on November 5, 2026, reviewing its July acquisition of Vidya Therapeutics and the concurrent private placement of approximately $200 million. The letter says the approximately 2.8 million common shares outstanding represent only a small part of an expected 309.3 million-share as-converted count after Series A preferred conversion, which is subject to stockholder approval. Stockholders must vote separately at two special meetings, and the company says the July financing is expected to fund operations into the second half of 2029.
Key points
- The Vidya acquisition and private placement closed in July; the financing generated approximately $183.3 million in net proceeds.
- Expected capitalization: 2.8 million common shares outstanding plus 306.5 million Series A preferred as-converted, for 309.3 million total, subject to stockholder approval.
- Definitive proxy materials for the first special meeting were filed October 22, 2026, and mailing has commenced; the second meeting's proxy is forthcoming.
- The FDA cleared the IND for a planned Phase 2 clinical trial of VT-7208 in chronic spontaneous urticaria.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.